10-Q: Quarterly report
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on "Therapeutic Over-Activation in Cancer"
Lixte Biotechnology Holdings Files $50M Offering
Lixte Biotechnology Holdings Files $50M Offering
Watching Lixte Biotechnology; White Diamond Research Posts On X "BREAKING NEWS: Lixte Biotechnology Lied: Its Publication Yesterday Isn't New – It's The Same One They Published Over A Year Ago"
White Diamond on X: "BREAKING NEWS: Lixte Biotechnology Lied: Its Publication Yesterday Isn't New – It's The Same One They Published Over A Year Ago $LIXT See news brief here: " / X (twitter.com)white
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks were rising late Wednesday afternoon, with the NYSE Health Care Index adding 0.8% and the Health Care Select Sector SPDR Fund (XLV) climbing 1%. The iShares Biotechnology ETF (IBB)
Lixte Stock Soars on Preclinical Data for Lead Drug LB-100
Top Midday Gainers
iBio's (IBIO) shares were up 211% amid heavy trading Wednesday, a day after the company said it signed a securities purchase agreement for a private investment in public equity financing with expected
SMR, GCTS and GSIW Among Mid-day Movers
Why Lixte Biotechnology Stock Is Soaring
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares are trading higher Wednesday after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100.The Details:
IBio, ImmunityBio, Mesoblast Among Healthcare Movers
Dow Jumps Over 200 Points; UniFirst Posts Downbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones gaining over 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.58% to 39,511.62 while the NASDAQ rose 0.60
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersLixte Biotechnology (NASDAQ:LIXT) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.4 million. Nutriband (NASDA
LIXTE Biotechnology Holdings Publication Pre-Clinical Data In Cancer Discovery Regarding LB-100
LIXTE Biotechnology Holdings Publication Pre-Clinical Data In Cancer Discovery Regarding LB-100
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS PASADENA, CA, March 27, 2024 (GLOBE NEWSWIRE) -- LIXTE
LIXTE Provides Update on Progress With LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company")
Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research
Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic PASADENA, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, I
LIXTE Biotechnology Enters Into Exclusive Immune Oncology Patent License Agreement With NINDS and NCI
Agreement Focuses on Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the
First Patient Dosed With LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess
Lixte Biotechnology Granted U.S. Patent # 11866444: Oxabicycloheptane Prodrugs
Lixte Biotechnology Granted U.S. Patent # 11866444: Oxabicycloheptane Prodrugs
Top Premarket Decliners
Tharimmune (THAR) shares slumped 69% Tuesday premarket after the company said late Monday it priced a $10 million public offering of common shares. SenesTech (SNES) shares tumbled 37%, a day after the
No Data